ClinicalTrials.Veeva

Menu

Pulmonary Vascular Impairment in Chronic Obstructive Pulmonary Disease (COPD) Assessed by MRI (PulmoVasc)

P

Public Assistance-Hospitals of Marseille (AP-HM)

Status

Completed

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Treatments

Diagnostic Test: chest Magnetic Resonance Imaging (MRI) using Gadolinium-based contrast agent

Study type

Interventional

Funder types

Other

Identifiers

NCT04126616
2019-14

Details and patient eligibility

About

Chronic Obstructive Pulmonary Disease (COPD) is a highly prevalent pulmonary disease providing major morbidity and mortality. Bronchial obstruction is the cornerstone in assessment of the disease whereas associated pulmonary vascular disease remains poorly known.

Improving knowledge on pulmonary vascular adaptive skills in COPD patients could allow for better understanding disease exacerbations, evolution towards chronic pulmonary hypertension (PH) and therapeutics to be offered to the patients.

Magnetic resonance imaging (MRI) is an innovative and non-invasive tool capable of pulmonary vascular evaluation. This work aims at identifying pulmonary vascular impairment in COPD patients using functional MRI.

Full description

Chronic Obstructive Pulmonary Disease (COPD) is a highly prevalent pulmonary disease providing major morbidity and mortality. Bronchial obstruction is the cornerstone in assessment of the disease whereas associated pulmonary vascular disease remains poorly known.

However, it has been shown that emphysema, frequently observed in COPD, contains major vascular lesions. Alteration of pulmonary vascularisation have been found during exacerbation of the disease.

Moreover, it is well established that such vascular lesions form the substrate for endothelial dysfunction, expressed as an impairment of vascular adaptation during exercise, and evolving towards chronic pulmonary hypertension (PH). Owing to its severe effects on the right-sided heart, it signs a pejorative turn in patients' survival and quality of life.

Finally, COPD patients' phenotypes are very heterogeneous and the clinical response to PH treatments is variable; while some get a benefit, others are counter-indicated due to adverse effects.

Improving knowledge on pulmonary vascular adaptive skills in COPD patients could allow for better understanding disease exacerbations, evolution towards PH and therapeutics to be offered to the patients.

This area of research remains widely unknown because of the lack of simple tools to assess pulmonary vascularisation which could be used in clinical routine. Magnetic resonance imaging (MRI) is an innovative and non-invasive tool capable of pulmonary vascular evaluation. This work aims at identifying pulmonary vascular impairment in COPD patients using functional MRI.

Enrollment

30 patients

Sex

All

Ages

40 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Age 40-70
  • Diagnosed with COPD
  • Emphysema on chest CT
  • FEV1 between 35 and 80 %
  • Screened for PH by echocardiography

Exclusion criteria

  • side effect for exercise
  • side effect for MRI and contrast agent injection
  • Pregnancy or breastfeeding
  • Refusing to be informed of the discovery of an anomaly on chest MRI

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

30 participants in 3 patient groups

patients with COPD and PH
Experimental group
Treatment:
Diagnostic Test: chest Magnetic Resonance Imaging (MRI) using Gadolinium-based contrast agent
patients with COPD without PH
Active Comparator group
Treatment:
Diagnostic Test: chest Magnetic Resonance Imaging (MRI) using Gadolinium-based contrast agent
healthy subjects
Active Comparator group
Treatment:
Diagnostic Test: chest Magnetic Resonance Imaging (MRI) using Gadolinium-based contrast agent

Trial contacts and locations

1

Loading...

Central trial contact

Thibaut Capron

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems